Gabather AB (publ) Asset Resilience Ratio
Gabather AB (publ) asset resilience ratio. Gabather AB (publ) (GABA) has an Asset Resilience Ratio of 82.06% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gabather AB (publ) defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gabather AB (publ) (2016–2025)
Asset resilience ratio of Gabather AB (publ) from 2016 to 2025. This chart shows how Gabather AB (publ)'s Asset Resilience Ratio has changed over time. Read Gabather AB (publ) (GABA) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gabather AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Gabather AB (publ) balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.14 Million | 82.06% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.14 Million | 82.06% |
Asset Resilience Insights
- Very High Liquidity: Gabather AB (publ) maintains exceptional liquid asset reserves at 82.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gabather AB (publ) Industry Peers by Asset Resilience Ratio
Compare Gabather AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Gabather AB (publ) Asset Resilience Ratio by Year (2016–2025)
Gabather AB (publ) asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Gabather AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.06% | Skr3.14 Million ≈ $338.24K |
Skr3.83 Million ≈ $412.17K |
+34.16pp |
| 2024-12-31 | 47.90% | Skr878.00K ≈ $94.49K |
Skr1.83 Million ≈ $197.26K |
+32.76pp |
| 2023-12-31 | 15.14% | Skr1.11 Million ≈ $119.99K |
Skr7.36 Million ≈ $792.48K |
-77.75pp |
| 2022-12-31 | 92.89% | Skr6.27 Million ≈ $674.97K |
Skr6.75 Million ≈ $726.62K |
-3.57pp |
| 2021-12-31 | 96.46% | Skr14.85 Million ≈ $1.60 Million |
Skr15.39 Million ≈ $1.66 Million |
+0.32pp |
| 2020-12-31 | 96.14% | Skr30.92 Million ≈ $3.33 Million |
Skr32.16 Million ≈ $3.46 Million |
-1.32pp |
| 2019-12-31 | 97.46% | Skr44.90 Million ≈ $4.83 Million |
Skr46.07 Million ≈ $4.96 Million |
+5.79pp |
| 2018-12-31 | 91.67% | Skr16.65 Million ≈ $1.79 Million |
Skr18.16 Million ≈ $1.95 Million |
+15.40pp |
| 2017-12-31 | 76.27% | Skr36.74 Million ≈ $3.95 Million |
Skr48.18 Million ≈ $5.18 Million |
-4.14pp |
| 2016-12-31 | 80.41% | Skr27.94 Million ≈ $3.01 Million |
Skr34.75 Million ≈ $3.74 Million |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more